When an organ is injured, our body initiates a healing process. If the injury is repeated or chronic, it can lead to an ...

Sequana Medical to Sponsor Liver Connect, 5 th Annual Conference of Chronic Liver Disease Foundation Ghent, Belgium – 20 March 2025 – Sequana ...

Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...

Understanding liver fibrosis progression through machine learning provides valuable insights into disease mechanisms, ...

Research analysts at Brookline Capital Management issued their Q3 2025 earnings per share estimates for shares of BioVie in a research report issued on Tuesday, March 18th. Brookline Capital ...

Sequana Medical announces 2024 Full Year Results and 2025 Outlookalfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...

Brookline Capital Management upgraded shares of BioVie (NASDAQ:BIVI – Free Report) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports. BioVie Stock Up 8.

Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High ...

Understanding pancreatic cancer symptoms can help individuals seek medical attention sooner, potentially improving outcomes.

In a US retrospective study of data on veterans with compensated cirrhosis, more than half progressed to complications after approximately 5 years.